{
    "id": 96,
    "premise": "none",
    "hypothesis": "Patient could receive treatment with vemurafenib for V600E mutation",
    "label": "entailment",
    "explanation": "Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Patient could receive treatment with vemurafenib for V600E mutation",
        "history explanation": [
            "0 iteration: Patient has common BRAF V600E mutation.\nvemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity.",
            "1 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib.",
            "2 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib.",
            "3 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib.\nCandidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option.",
            "4 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive vemurafenib as a treatment option.\nCandidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option.",
            "5 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive vemurafenib as a treatment option. This potential is directly linked to their mutation status.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.",
            "6 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib. Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option.\nThis potential is directly linked to their mutation status.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.",
            "7 iteration: Patient has a common BRAF V600E mutation.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nPatients with a BRAF V600E mutation are candidates for treatment with vemurafenib. Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option.\nThis potential is directly linked to their mutation status.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.",
            "8 iteration: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nBeing a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option.\nThe potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.",
            "9 iteration: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nBeing a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option.\nThe potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.",
            "10 iteration: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib.\nVemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity.\nBeing a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option.\nThe potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation.\nCandidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option.\nIf a patient is likely to receive vemurafenib as a treatment option, then they could actually receive vemurafenib for their BRAF V600E mutation."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\nfrom explanation_1 obtain y where \"BRAF_V600E_Mutation y \u2227 Has x y\" sledgehammer', 'solving time': 103.48671340942383, 'proof tactics': [], 'code': 'theory clinical_96_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  Location :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Activity :: \"entity \u21d2 entity\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Instrument :: \"event \u21d2 entity \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  V600E_Mutation :: \"entity\"  (* Defined as an entity *)\\n\\n(* Explanation 1: Patient has common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Has x y\"\\n\\n(* Explanation 2: vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATPbinding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor x \u2227 LowMolecularWeight x \u2227 OrallyAvailable x \u2227 ATPBindingSite y \u2227 BRAF_V600E_Kinase z \u2227 Bind e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Location y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 PatientEvent e2 (Activity z)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 Instrument e z \u2227 For e V600E_Mutation\"\\nproof -\\n  (* From the premise, we have known information about the patient and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n  from explanation_1 obtain y where \"BRAF_V600E_Mutation y \u2227 Has x y\" <ATP>\\n  (* Explanation 2 provides that vemurafenib is a low-molecular-weight, orally available inhibitor, which binds and inhibits BRAF V600E kinase. *)\\n  from explanation_2 have \"Vemurafenib z \u2227 Inhibitor z \u2227 LowMolecularWeight z \u2227 OrallyAvailable z\" <ATP>\\n  (* Using the logical relation Implies(B, D), we can infer that vemurafenib inhibits the activity of BRAF V600E kinase. *)\\n  then have \"Inhibit e2 \u2227 Agent e2 z \u2227 PatientEvent e2 (Activity (BRAF_V600E_Kinase y))\" <ATP>\\n  (* We can now construct the event where the patient receives treatment with vemurafenib for the V600E mutation. *)\\n  let ?e = \"e2\"\\n  have \"Receive ?e \u2227 Agent ?e x \u2227 PatientEvent ?e (Treatment y) \u2227 Instrument ?e z \u2227 For ?e V600E_Mutation\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor (from Explanatory Sentence 2)\\nC: vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase (from Explanatory Sentence 2)\\nD: vemurafenib inhibits the activity of BRAF V600E kinase (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(B, C)\\nImplies(vemurafenib is a low-molecular-weight, orally available inhibitor, vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase)\\n--------\\nImplies(C, D)\\nImplies(vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase, vemurafenib inhibits the activity of BRAF V600E kinase)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(B))\\nImplies(Not(vemurafenib inhibits the activity of BRAF V600E kinase), Not(vemurafenib is a low-molecular-weight, orally available inhibitor))\\n--------\\nImplies(B, D)\\nImplies(vemurafenib is a low-molecular-weight, orally available inhibitor, vemurafenib inhibits the activity of BRAF V600E kinase)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 8.710307359695435, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient :: entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600EMutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600EKinase :: \"entity \u21d2 bool\"\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  Activity :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientRole :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient predicate *)\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 BRAF_V600EMutation y \u2227 Has x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w v e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 BRAF_V600EKinase z \u2227 ATPBindingSite w \u2227 Activity v \u2227 Bind e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 PatientRole e1 w \u2227 To w z \u2227 Agent e2 x \u2227 PatientRole e2 v\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w. Patient x \u2227 BRAF_V600EMutation y \u2227 Treatment z \u2227 Vemurafenib w \u2227 Candidate x \u2227 With x y \u2227 For z w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Vemurafenib z \u2227 V600EMutation w\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600EMutation w \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With y z \u2227 For y w\"\\nproof -\\n  (* From the premise, we have known information about the patient, vemurafenib, and V600E mutation. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 V600EMutation w\" <ATP>\\n  (* Explanation 1 states that a patient has a common BRAF V600E mutation. *)\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* There is a logical relation Implies(A, C), Implies(patient has a common BRAF V600E mutation, patients with a BRAF V600E mutation are candidates for treatment with vemurafenib) *)\\n  (* From the known information and explanation 3, we can infer that the patient is a candidate for treatment with vemurafenib. *)\\n  then have \"Candidate x \u2227 Treatment y \u2227 With x w \u2227 For y z\" <ATP>\\n  (* We can now conclude that the patient could receive treatment with vemurafenib for the V600E mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity (from Explanatory Sentence 2)\\nC: patients with a BRAF V600E mutation are candidates for treatment with vemurafenib (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(patient has a common BRAF V600E mutation, patients with a BRAF V600E mutation are candidates for treatment with vemurafenib)\\n--------\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n(* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n(* There is a logical relation Implies(A, D), Implies(patient has a common BRAF V600E mutation, patients with a BRAF V600E mutation are candidates for treatment with vemurafenib) *)\\n(* From the known information and explanation 3, we can infer that the patient is a candidate for treatment with vemurafenib. *)\\nthen have \"\u2203y z. Treatment y \u2227 Vemurafenib z \u2227 With y z \u2227 For y w\" sledgehammer', 'solving time': 103.77786135673523, 'proof tactics': [], 'code': 'theory clinical_96_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600EMutation :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600EKinase :: \"entity \u21d2 bool\"\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient *)\\n  Selectively :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Activity :: \"entity \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 BRAF_V600EMutation y \u2227 Has x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 v. Vemurafenib x \u2227 Inhibitor y \u2227 BRAF_V600EKinase z \u2227 ATPBindingSite w \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 Bind e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 PatientEvent e1 w \u2227 Selectively e1 \u2227 To w z \u2227 Activity v \u2227 PatientEvent e2 v\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w. Patient x \u2227 BRAF_V600EMutation y \u2227 Candidate x \u2227 Treatment z \u2227 Vemurafenib w \u2227 With z w \u2227 For x z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 V600EMutation w\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 V600EMutation w \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y w\"\\nproof -\\n  (* From the premise, we have known information about the patient and V600E mutation. *)\\n  from asm have \"Patient x \u2227 V600EMutation w\" <ATP>\\n  (* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* There is a logical relation Implies(A, D), Implies(patient has a common BRAF V600E mutation, patients with a BRAF V600E mutation are candidates for treatment with vemurafenib) *)\\n  (* From the known information and explanation 3, we can infer that the patient is a candidate for treatment with vemurafenib. *)\\n  then have \"\u2203y z. Treatment y \u2227 Vemurafenib z \u2227 With y z \u2227 For y w\" <ATP>\\n  (* We can now conclude that the patient could receive treatment with vemurafenib for V600E mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: vemurafenib is a low-molecular-weight, orally available inhibitor (from Explanatory Sentence 2)\\nC: vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity (from Explanatory Sentence 2)\\nD: patients with a BRAF V600E mutation are candidates for treatment with vemurafenib (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, D)\\nImplies(patient has a common BRAF V600E mutation, patients with a BRAF V600E mutation are candidates for treatment with vemurafenib)\\n--------\\nImplies(B, C)\\nImplies(vemurafenib is a low-molecular-weight, orally available inhibitor, vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n(* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n(* Explanation 4 states that candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\n(* Using the derived implication Implies(A, D), we can infer that a patient with a BRAF V600E mutation has the potential to receive vemurafenib. *)\\nthen have \"\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\" sledgehammer', 'solving time': 103.24595355987549, 'proof tactics': [], 'code': 'theory clinical_96_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E :: \"entity \u21d2 bool\"\\n  Has :: \"event \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Binds :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  Inhibits :: \"event \u21d2 bool\"\\n  Activity :: \"event \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Potential :: \"event \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  AsOption :: \"entity \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Patient x \u2227 Mutation y \u2227 Common y \u2227 BRAF_V600E y \u2227 Has e x \u2227 Agent e y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 Binds e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 ATPBindingSite z \u2227 BRAF_V600E z \u2227 Inhibits e2 \u2227 Agent e2 x \u2227 Activity e2\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Mutation y \u2227 BRAF_V600E y \u2227 Candidate x \u2227 Treatment z \u2227 Vemurafenib z \u2227 For z x\"\\n\\n(* Explanation 4: Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. Candidate x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Potential e \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e z \u2227 AsOption y z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\"\\nproof -\\n  (* From the premise, we have known information about the patient, treatment, and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Explanation 4 states that candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\n  (* Using the derived implication Implies(A, D), we can infer that a patient with a BRAF V600E mutation has the potential to receive vemurafenib. *)\\n  then have \"\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib inhibits the activity of BRAF V600E kinase (from Explanatory Sentence 2)\\nC: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib (from Explanatory Sentence 3)\\nD: Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has a common BRAF V600E mutation, Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib, Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has a common BRAF V600E mutation, Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n(* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n(* Explanation 4 states that candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\n(* Using the logical relation Implies(A, D), we can infer that a patient with a BRAF V600E mutation has the potential to receive vemurafenib. *)\\nfrom explanation_1 and explanation_3 and explanation_4 have \"\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\" sledgehammer', 'solving time': 103.48203873634338, 'proof tactics': [], 'code': 'theory clinical_96_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Common :: \"entity \u21d2 bool\"\\n  BRAF_V600E :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  LowMolecularWeight :: \"entity \u21d2 bool\"\\n  OrallyAvailable :: \"entity \u21d2 bool\"\\n  Binds :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  ATPBindingSite :: \"entity \u21d2 bool\"\\n  Selectively :: \"event \u21d2 bool\"\\n  Inhibits :: \"event \u21d2 bool\"\\n  Activity :: \"entity \u21d2 bool\"\\n  Candidate :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Potential :: \"event \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Mutation y \u2227 Common y \u2227 BRAF_V600E y \u2227 Has x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 LowMolecularWeight y \u2227 OrallyAvailable y \u2227 Binds e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 ATPBindingSite z \u2227 BRAF_V600E z \u2227 Selectively e1 \u2227 Inhibits e2 \u2227 Agent e2 x \u2227 Activity z\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Patient x \u2227 Mutation y \u2227 BRAF_V600E y \u2227 Candidate e1 \u2227 Agent e1 x \u2227 Treatment z \u2227 Vemurafenib z \u2227 For z y \u2227 Potential e2 \u2227 Agent e2 x \u2227 Receive e2 \u2227 PatientEvent e2 z\"\\n\\n(* Explanation 4: Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1 e2. Candidate e1 \u2227 Treatment y \u2227 Vemurafenib y \u2227 For y y \u2227 Potential e1 \u2227 Agent e1 x \u2227 Receive e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Vemurafenib z \u2227 Treatment y\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\"\\nproof -\\n  (* From the known information, we have Patient x, Vemurafenib z, and Treatment y. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 Treatment y\" <ATP>\\n  \\n  (* Explanation 1 provides that a patient has a common BRAF V600E mutation. *)\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Explanation 4 states that candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option. *)\\n  (* Using the logical relation Implies(A, D), we can infer that a patient with a BRAF V600E mutation has the potential to receive vemurafenib. *)\\n  from explanation_1 and explanation_3 and explanation_4 have \"\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y V600E\" <ATP>\\n  \\n  (* Combining the above with the known information, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib inhibits the activity of BRAF V600E kinase (from Explanatory Sentence 2)\\nC: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib (from Explanatory Sentence 3)\\nD: Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has a common BRAF V600E mutation, Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib, Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has a common BRAF V600E mutation, Candidates for treatment with vemurafenib have the potential to receive vemurafenib as a treatment option)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive it. *)\\n(* Using the logical relation Implies(C, D), we can infer that patients have the potential to receive vemurafenib as a treatment option. *)\\nfrom explanation_3 have \"\u2203x y z v w e1 e2. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Candidate z \u2227 Treatment w \u2227 Vemurafenib v \u2227 Have e1 \u2227 Receive e2 \u2227 Agent e1 x \u2227 Patient z \u2227 For e1 w \u2227 Agent e2 x \u2227 Patient v \u2227 As e2 w\" sledgehammer', 'solving time': 119.0542368888855, 'proof tactics': [], 'code': 'theory clinical_96_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Selectively :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  As :: \"event \u21d2 entity \u21d2 bool\"\\n  Potential :: \"entity \u21d2 bool\"\\n  Mutation_Status :: \"entity \u21d2 bool\"\\n  Linked :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Likely :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Has e \u2227 Agent e x \u2227 Patient y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 BRAF_V600E_Kinase z \u2227 ATP_Binding_Site w \u2227 Bind e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 Patient w \u2227 Selectively e1 \u2227 Agent e2 x \u2227 Patient z \u2227 To e1 w\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z v w e1 e2. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Candidate z \u2227 Treatment w \u2227 Vemurafenib v \u2227 Have e1 \u2227 Receive e2 \u2227 Agent e1 x \u2227 Patient z \u2227 For e1 w \u2227 Agent e2 x \u2227 Patient v \u2227 As e2 w\"\\n\\n(* Explanation 4: This potential is directly linked to their mutation status. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e. Potential x \u2227 Mutation_Status y \u2227 Linked e \u2227 Agent e x \u2227 Patient y \u2227 Directly e\"\\n\\n(* Explanation 5: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e. Candidate x \u2227 Treatment y \u2227 Vemurafenib z \u2227 BRAF_V600E_Mutation w \u2227 Receive e \u2227 Agent e x \u2227 Patient z \u2227 As e y \u2227 Likely e\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient y \u2227 Instrument e z \u2227 For e V600E_Mutation\"\\nproof -\\n  (* From the known information, we have Patient x, Treatment y, and Vemurafenib z. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 provides that a patient has a common BRAF V600E mutation, which implies they are candidates for treatment with vemurafenib. *)\\n  (* Using the logical relation Implies(A, C), we can infer that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  from explanation_1 have \"\u2203x y e. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Has e \u2227 Agent e x \u2227 Patient y\" <ATP>\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib and have the potential to receive it. *)\\n  (* Using the logical relation Implies(C, D), we can infer that patients have the potential to receive vemurafenib as a treatment option. *)\\n  from explanation_3 have \"\u2203x y z v w e1 e2. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Candidate z \u2227 Treatment w \u2227 Vemurafenib v \u2227 Have e1 \u2227 Receive e2 \u2227 Agent e1 x \u2227 Patient z \u2227 For e1 w \u2227 Agent e2 x \u2227 Patient v \u2227 As e2 w\" <ATP>\\n  (* Explanation 5 states that candidates for treatment with vemurafenib are likely to receive it. *)\\n  (* Using the logical relation Implies(C, F), we can infer that candidates for treatment with vemurafenib are likely to receive it. *)\\n  from explanation_5 have \"\u2203x y z w e. Candidate x \u2227 Treatment y \u2227 Vemurafenib z \u2227 BRAF_V600E_Mutation w \u2227 Receive e \u2227 Agent e x \u2227 Patient z \u2227 As e y \u2227 Likely e\" <ATP>\\n  (* Therefore, we can conclude that a patient could receive treatment with vemurafenib for V600E mutation. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib inhibits the activity of BRAF V600E kinase (from Explanatory Sentence 2)\\nC: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib (from Explanatory Sentence 3)\\nD: Patients have the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 3)\\nE: This potential is directly linked to their mutation status (from Explanatory Sentence 4)\\nF: Candidates for treatment with vemurafenib are likely to receive vemurafenib as a treatment option (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has a common BRAF V600E mutation, Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib, Patients have the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(A, E)\\nImplies(Patient has a common BRAF V600E mutation, This potential is directly linked to their mutation status)\\n--------\\nImplies(C, F)\\nImplies(Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib, Candidates for treatment with vemurafenib are likely to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(Patients have the potential to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has a common BRAF V600E mutation, Patients have the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(Candidates for treatment with vemurafenib are likely to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, F)\\nImplies(Patient has a common BRAF V600E mutation, Candidates for treatment with vemurafenib are likely to receive vemurafenib as a treatment option)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 7.42254376411438, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  For :: entity \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  PotentialToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Potential :: \"entity \u21d2 bool\"\\n  MutationStatus :: \"entity \u21d2 bool\"\\n  LinkedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  As :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  Instrument :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Has e \u2227 Agent e x \u2227 Agent e y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 BRAF_V600E_Kinase z \u2227 ATP_Binding_Site z \u2227 Bind e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 Agent e1 z \u2227 Agent e2 x \u2227 Agent e2 z\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Candidate z \u2227 For z y \u2227 Treatment y \u2227 With z x \u2227 Vemurafenib x\"\\n\\n(* Explanation 4: Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_4: \"\u2200x z. Candidate x \u2227 Vemurafenib z \u27f6 PotentialToReceive x z\"\\n\\n(* Explanation 5: This potential is directly linked to their mutation status. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y. Potential x \u2227 MutationStatus y \u27f6 LinkedTo x y\"\\n\\n(* Explanation 6: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e. Candidate x \u2227 BRAF_V600E_Mutation y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e z \u2227 As e z \u2227 TreatmentOption z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Vemurafenib z \u2227 Treatment y\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 Instrument e z \u2227 For e y\"\\nproof -\\n  (* From the known information, we have Patient x, Vemurafenib z, and Treatment y. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 Treatment y\" <ATP>\\n  \\n  (* Explanation 1 and the logical relation Implies(A, C) tell us that if a patient has a BRAF V600E mutation, they are a candidate for treatment with vemurafenib. *)\\n  (* Explanation 3 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Therefore, we can infer that Patient x is a candidate for treatment with vemurafenib. *)\\n  then have \"Candidate x\" <ATP>\\n  \\n  (* Explanation 4 and the logical relation Implies(C, D) tell us that being a candidate for treatment with vemurafenib implies having the potential to receive vemurafenib as a treatment option. *)\\n  (* Therefore, we can infer that Patient x has the potential to receive vemurafenib. *)\\n  then have \"PotentialToReceive x z\" <ATP>\\n  \\n  (* Explanation 6 and the logical relation Implies(C, F) tell us that candidates for treatment with vemurafenib are likely to receive vemurafenib as a treatment option. *)\\n  (* Therefore, we can infer that Patient x is likely to receive vemurafenib. *)\\n  then have \"Receive e\" <ATP>\\n  \\n  (* We now have all the components needed to construct the hypothesis. *)\\n  then show \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 Instrument e z \u2227 For e y\" <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib inhibits BRAF V600E kinase activity (from Explanatory Sentence 2)\\nC: Patient is a candidate for treatment with vemurafenib (from Explanatory Sentence 3)\\nD: Patient has the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 4)\\nE: Potential to receive vemurafenib is linked to mutation status (from Explanatory Sentence 5)\\nF: Patient is likely to receive vemurafenib as a treatment option (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has a common BRAF V600E mutation, Patient is a candidate for treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Patient is a candidate for treatment with vemurafenib, Patient has the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(D, E)\\nImplies(Patient has the potential to receive vemurafenib as a treatment option, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(C, F)\\nImplies(Patient is a candidate for treatment with vemurafenib, Patient is likely to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(Potential to receive vemurafenib is linked to mutation status), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, E)\\nImplies(Patient has a common BRAF V600E mutation, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(A, F)\\nImplies(Patient has a common BRAF V600E mutation, Patient is likely to receive vemurafenib as a treatment option)\\n--------\\nImplies(C, E)\\nImplies(Patient is a candidate for treatment with vemurafenib, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Potential to receive vemurafenib is linked to mutation status), Not(Patient is a candidate for treatment with vemurafenib))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(Patient has the potential to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has a common BRAF V600E mutation, Patient has the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(Patient is likely to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': 'then have \"Candidate x\" sledgehammer', 'solving time': 118.66590356826782, 'proof tactics': [], 'code': 'theory clinical_96_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Has :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  PotentialToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Potential :: \"entity \u21d2 bool\"\\n  MutationStatus :: \"entity \u21d2 bool\"\\n  Linked :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  AsOption :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient has a common BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x e. Patient x \u2227 BRAF_V600E_Mutation x \u2227 Has e \u2227 Agent e x\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor y \u2227 BRAF_V600E_Kinase z \u2227 ATP_Binding_Site z \u2227 Bind e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 Agent e2 x \u2227 Agent e1 z \u2227 Agent e2 z\"\\n\\n(* Explanation 3: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w. Patient x \u2227 BRAF_V600E_Mutation x \u2227 Candidate z \u2227 For z y \u2227 Treatment y \u2227 With y w \u2227 Vemurafenib w\"\\n\\n(* Explanation 4: Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z. Candidate x \u2227 Treatment y \u2227 Vemurafenib z \u27f6 PotentialToReceive x z\"\\n\\n(* Explanation 5: This potential is directly linked to their mutation status. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y. Potential x \u2227 MutationStatus y \u27f6 Linked x y\"\\n\\n(* Explanation 6: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e w. Candidate x \u2227 BRAF_V600E_Mutation x \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e z \u2227 AsOption z w \u2227 Treatment w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Vemurafenib z \u2227 For y V600E\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y V600E\"\\nproof -\\n  (* From the known information, we have Patient x and Vemurafenib z. *)\\n  from asm have \"Patient x \u2227 Vemurafenib z \u2227 For y V600E\" <ATP>\\n  (* Explanation 1 and logical relation Implies(A, C) imply that a patient with a BRAF V600E mutation is a candidate for treatment with vemurafenib. *)\\n  from explanation_1 have \"\u2203x. Patient x \u2227 BRAF_V600E_Mutation x\" <ATP>\\n  then have \"Candidate x\" <ATP>\\n  (* Explanation 4 and logical relation Implies(C, D) imply that being a candidate implies having the potential to receive vemurafenib. *)\\n  then have \"PotentialToReceive x z\" <ATP>\\n  (* Explanation 6 and logical relation Implies(C, F) imply that candidates are likely to receive vemurafenib as a treatment option. *)\\n  then have \"Receive e\" <ATP>\\n  (* We can now construct the hypothesis statement. *)\\n  then show \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y V600E\" <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient has a common BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Vemurafenib inhibits BRAF V600E kinase activity (from Explanatory Sentence 2)\\nC: Patient is a candidate for treatment with vemurafenib (from Explanatory Sentence 3)\\nD: Patient has the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 4)\\nE: Potential to receive vemurafenib is linked to mutation status (from Explanatory Sentence 5)\\nF: Patient is likely to receive vemurafenib as a treatment option (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(Patient has a common BRAF V600E mutation, Patient is a candidate for treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Patient is a candidate for treatment with vemurafenib, Patient has the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(D, E)\\nImplies(Patient has the potential to receive vemurafenib as a treatment option, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(C, F)\\nImplies(Patient is a candidate for treatment with vemurafenib, Patient is likely to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(Potential to receive vemurafenib is linked to mutation status), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, E)\\nImplies(Patient has a common BRAF V600E mutation, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(A, F)\\nImplies(Patient has a common BRAF V600E mutation, Patient is likely to receive vemurafenib as a treatment option)\\n--------\\nImplies(C, E)\\nImplies(Patient is a candidate for treatment with vemurafenib, Potential to receive vemurafenib is linked to mutation status)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Potential to receive vemurafenib is linked to mutation status), Not(Patient is a candidate for treatment with vemurafenib))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(Patient has the potential to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\nImplies(A, D)\\nImplies(Patient has a common BRAF V600E mutation, Patient has the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(Patient is likely to receive vemurafenib as a treatment option), Not(Patient has a common BRAF V600E mutation))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 7.737376928329468, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   Receive e :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_96_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient_event :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Potential :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Presence :: \"entity \u21d2 entity \u21d2 bool\"\\n  Likely :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z u. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Treatment z \u2227 With z u \u2227 Vemurafenib u \u2227 Candidate x z \u27f6 With x y\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Vemurafenib x \u2227 Inhibitor x \u2227 ATP_Binding_Site y \u2227 BRAF_V600E_Kinase z \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient_event e1 y \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient_event e2 z\"\\n\\n(* Explanation 3: Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z u. Candidate x y \u2227 Treatment y \u2227 With y u \u2227 Vemurafenib u \u27f6 Potential x z \u2227 Receive z y\"\\n\\n(* Explanation 4: The potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y u. Potential x u \u2227 Vemurafenib u \u2227 Receive x u \u27f6 (\u2203v. Presence y v \u2227 BRAF_V600E_Mutation v)\"\\n\\n(* Explanation 5: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y z u. Candidate x y \u2227 Treatment y \u2227 With y u \u2227 Vemurafenib u \u2227 BRAF_V600E_Mutation z \u27f6 Likely x u \u2227 Receive x u\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient_event e y \u2227 With y z \u2227 For y v\"\\nproof -\\n  (* From the premise, we have known information about the patient, treatment, and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 and the logical relation Implies(A, B) suggest that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Explanation 3 and the logical relation Implies(B, E) suggest that being a candidate implies having the potential to receive vemurafenib. *)\\n  (* Explanation 4 and the logical relation Implies(E, F) suggest that the potential to receive vemurafenib is linked to the presence of a BRAF V600E mutation. *)\\n  (* Explanation 5 and the logical relation Implies(B, G) suggest that candidates are likely to receive vemurafenib. *)\\n  (* We can infer that the patient could receive treatment with vemurafenib for V600E mutation. *)\\n  then have \"\u2203e. Receive e \u2227 Agent e x \u2227 Patient_event e y \u2227 With y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have a BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Candidates for treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Vemurafenib is a low-molecular-weight, orally available inhibitor (from Explanatory Sentence 2)\\nD: Vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity (from Explanatory Sentence 2)\\nE: Having the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 3)\\nF: Presence of a BRAF V600E mutation (from Explanatory Sentence 4)\\nG: Likely to receive vemurafenib as a treatment option (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have a BRAF V600E mutation, Candidates for treatment with vemurafenib)\\n--------\\nImplies(B, E)\\nImplies(Candidates for treatment with vemurafenib, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(E, F)\\nImplies(Having the potential to receive vemurafenib as a treatment option, Presence of a BRAF V600E mutation)\\n--------\\nImplies(B, G)\\nImplies(Candidates for treatment with vemurafenib, Likely to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(Having the potential to receive vemurafenib as a treatment option), Not(Patients have a BRAF V600E mutation))\\n--------\\nImplies(A, E)\\nImplies(Patients have a BRAF V600E mutation, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Likely to receive vemurafenib as a treatment option), Not(Patients have a BRAF V600E mutation))\\n--------\\nImplies(A, F)\\nImplies(Patients have a BRAF V600E mutation, Presence of a BRAF V600E mutation)\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(Presence of a BRAF V600E mutation), Not(Candidates for treatment with vemurafenib))\\n--------\\nImplies(A, G)\\nImplies(Patients have a BRAF V600E mutation, Likely to receive vemurafenib as a treatment option)\\n--------\\nImplies(B, F)\\nImplies(Candidates for treatment with vemurafenib, Presence of a BRAF V600E mutation)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(Presence of a BRAF V600E mutation), Not(Patients have a BRAF V600E mutation))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 and logical relation Implies(A, B) suggest that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n(* Explanation 3 and logical relation Implies(B, E) suggest that being a candidate for treatment with vemurafenib implies having the potential to receive it. *)\\n(* Explanation 5 and logical relation Implies(B, G) suggest that candidates for treatment with vemurafenib are likely to receive it. *)\\n(* We can infer that the patient is likely to receive treatment with vemurafenib. *)\\nthen have \"LikelyToReceive x z\" sledgehammer', 'solving time': 103.46514320373535, 'proof tactics': [], 'code': 'theory clinical_96_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  CandidateFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient *)\\n  Selectively :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  DirectlyImplies :: \"entity \u21d2 entity \u21d2 bool\"  (* Changed to take two entities *)\\n  PotentialToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  DirectlyLinkedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  LikelyToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z. (Patient x \u2227 BRAF_V600E_Mutation y \u2227 Treatment z \u2227 With x y) \u27f6 (CandidateFor x z \u2227 With z x)\"  (* Corrected With usage *)\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e1 e2. Vemurafenib x \u2227 Inhibitor x \u2227 BRAF_V600E_Kinase y \u2227 ATP_Binding_Site z \u2227 Bind e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 Selectively e1 \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y\"\\n\\n(* Explanation 3: Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. (CandidateFor x y \u2227 Treatment y \u2227 Vemurafenib z) \u27f6 DirectlyImplies x z\"  (* Corrected DirectlyImplies usage *)\\n\\n(* Explanation 4: The potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. (PotentialToReceive x y \u2227 BRAF_V600E_Mutation y) \u27f6 DirectlyLinkedTo x y\"  (* Corrected PotentialToReceive usage *)\\n\\n(* Explanation 5: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y z. (CandidateFor x y \u2227 Treatment y \u2227 Vemurafenib z \u2227 BRAF_V600E_Mutation x) \u27f6 LikelyToReceive x z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y z\"  (* Corrected For usage *)\\nproof -\\n  (* From the premise, we have known information about the patient, treatment, and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 and logical relation Implies(A, B) suggest that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Explanation 3 and logical relation Implies(B, E) suggest that being a candidate for treatment with vemurafenib implies having the potential to receive it. *)\\n  (* Explanation 5 and logical relation Implies(B, G) suggest that candidates for treatment with vemurafenib are likely to receive it. *)\\n  (* We can infer that the patient is likely to receive treatment with vemurafenib. *)\\n  then have \"LikelyToReceive x z\" <ATP>\\n  (* From the derived implication Implies(A, G), we know that patients with a BRAF V600E mutation are likely to receive vemurafenib. *)\\n  (* Therefore, we can conclude that the patient could receive treatment with vemurafenib for V600E mutation. *)\\n  then have \"Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have a BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Patients are candidates for treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Vemurafenib is a low-molecular-weight, orally available inhibitor (from Explanatory Sentence 2)\\nD: Vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity (from Explanatory Sentence 2)\\nE: Having the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 3)\\nF: Presence of a BRAF V600E mutation (from Explanatory Sentence 4)\\nG: Likely to receive vemurafenib as a treatment option (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have a BRAF V600E mutation, Patients are candidates for treatment with vemurafenib)\\n--------\\nImplies(B, E)\\nImplies(Patients are candidates for treatment with vemurafenib, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(E, F)\\nImplies(Having the potential to receive vemurafenib as a treatment option, Presence of a BRAF V600E mutation)\\n--------\\nImplies(B, G)\\nImplies(Patients are candidates for treatment with vemurafenib, Likely to receive vemurafenib as a treatment option)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(Having the potential to receive vemurafenib as a treatment option), Not(Patients have a BRAF V600E mutation))\\n--------\\nImplies(A, E)\\nImplies(Patients have a BRAF V600E mutation, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Likely to receive vemurafenib as a treatment option), Not(Patients have a BRAF V600E mutation))\\n--------\\nImplies(A, F)\\nImplies(Patients have a BRAF V600E mutation, Presence of a BRAF V600E mutation)\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(Presence of a BRAF V600E mutation), Not(Patients are candidates for treatment with vemurafenib))\\n--------\\nImplies(A, G)\\nImplies(Patients have a BRAF V600E mutation, Likely to receive vemurafenib as a treatment option)\\n--------\\nImplies(B, F)\\nImplies(Patients are candidates for treatment with vemurafenib, Presence of a BRAF V600E mutation)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(Presence of a BRAF V600E mutation), Not(Patients have a BRAF V600E mutation))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n(* Explanation 3 states that being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\n(* Explanation 5 states that candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\n(* Explanation 6 states that if a patient is likely to receive vemurafenib as a treatment option, then they could actually receive vemurafenib for their BRAF V600E mutation. *)\\n(* Using the logical relations and derived implications, we can infer the hypothesis. *)\\nhave \"Candidate x z\" sledgehammer', 'solving time': 103.37145614624023, 'proof tactics': [], 'code': 'theory clinical_96_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Mutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Candidate :: \"entity \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  BRAF_V600E_Kinase :: \"entity \u21d2 bool\"\\n  ATP_Binding_Site :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid clash *)\\n  Inhibit :: \"event \u21d2 bool\"\\n  Selectively :: \"event \u21d2 bool\"\\n  PotentialToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  LinkedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  LikelyToReceive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z. Patient x \u2227 BRAF_V600E_Mutation y \u2227 Treatment z \u2227 Vemurafenib z \u27f6 (Candidate x z \u2227 With x y)\"\\n\\n(* Explanation 2: Vemurafenib is a low-molecular-weight, orally available inhibitor which selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e1 e2. Vemurafenib x \u2227 Inhibitor x \u2227 BRAF_V600E_Kinase y \u2227 ATP_Binding_Site z \u2227 Bind e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y \u2227 Selectively e1 \u2227 Selectively e2\"\\n\\n(* Explanation 3: Being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. Candidate x y \u2227 Treatment y \u2227 Vemurafenib z \u27f6 PotentialToReceive x z\"\\n\\n(* Explanation 4: The potential to receive vemurafenib is directly linked to the presence of a BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z. PotentialToReceive x y \u2227 Vemurafenib y \u2227 BRAF_V600E_Mutation z \u27f6 LinkedTo x z\"\\n\\n(* Explanation 5: Candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y z. Candidate x y \u2227 Treatment y \u2227 Vemurafenib z \u2227 BRAF_V600E_Mutation x \u27f6 LikelyToReceive x z\"\\n\\n(* Explanation 6: If a patient is likely to receive vemurafenib as a treatment option, then they could actually receive vemurafenib for their BRAF V600E mutation. *)\\naxiomatization where\\n  explanation_6: \"\u2200x y z. Patient x \u2227 Vemurafenib y \u2227 BRAF_V600E_Mutation z \u2227 LikelyToReceive x y \u27f6 (\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 For y z)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\"\\n  (* Hypothesis: Patient could receive treatment with vemurafenib for V600E mutation. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 PatientEvent e y \u2227 With y z \u2227 For y z\"\\nproof -\\n  (* From the premise, we have known information about the patient, treatment, and vemurafenib. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Vemurafenib z\" <ATP>\\n  (* Explanation 1 states that patients with a BRAF V600E mutation are candidates for treatment with vemurafenib. *)\\n  (* Explanation 3 states that being a candidate for treatment with vemurafenib directly implies having the potential to receive vemurafenib as a treatment option. *)\\n  (* Explanation 5 states that candidates for treatment with vemurafenib, due to their BRAF V600E mutation, are likely to receive vemurafenib as a treatment option. *)\\n  (* Explanation 6 states that if a patient is likely to receive vemurafenib as a treatment option, then they could actually receive vemurafenib for their BRAF V600E mutation. *)\\n  (* Using the logical relations and derived implications, we can infer the hypothesis. *)\\n  have \"Candidate x z\" <ATP>\\n  then have \"PotentialToReceive x z\" <ATP>\\n  then have \"LikelyToReceive x z\" <ATP>\\n  then have \"\u2203e. Receive e \u2227 Agent e x \u2227 PatientEvent e z \u2227 For z y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have a BRAF V600E mutation (from Explanatory Sentence 1)\\nB: Patients are candidates for treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Vemurafenib is a low-molecular-weight, orally available inhibitor (from Explanatory Sentence 2)\\nD: Vemurafenib selectively binds to the ATP-binding site of BRAF V600E kinase and inhibits its activity (from Explanatory Sentence 2)\\nE: Having the potential to receive vemurafenib as a treatment option (from Explanatory Sentence 3)\\nF: Likely to receive vemurafenib as a treatment option (from Explanatory Sentence 5)\\nG: Could actually receive vemurafenib for their BRAF V600E mutation (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have a BRAF V600E mutation, Patients are candidates for treatment with vemurafenib)\\n--------\\nImplies(B, E)\\nImplies(Patients are candidates for treatment with vemurafenib, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nEquivalent(E, A)\\nEquivalent(Patients have a BRAF V600E mutation, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(F, G)\\nImplies(Likely to receive vemurafenib as a treatment option, Could actually receive vemurafenib for their BRAF V600E mutation)\\n--------\\n\\nDerived Implications:\\nImplies(B, A)\\nImplies(Patients are candidates for treatment with vemurafenib, Patients have a BRAF V600E mutation)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Patients have a BRAF V600E mutation), Not(Patients are candidates for treatment with vemurafenib))\\n--------\\nImplies(A, E)\\nImplies(Patients have a BRAF V600E mutation, Having the potential to receive vemurafenib as a treatment option)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Patients are candidates for treatment with vemurafenib), Not(Having the potential to receive vemurafenib as a treatment option))\\n--------\\nImplies(E, A)\\nImplies(Having the potential to receive vemurafenib as a treatment option, Patients have a BRAF V600E mutation)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Patients have a BRAF V600E mutation), Not(Having the potential to receive vemurafenib as a treatment option))\\n--------\\nImplies(E, B)\\nImplies(Having the potential to receive vemurafenib as a treatment option, Patients are candidates for treatment with vemurafenib)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(Having the potential to receive vemurafenib as a treatment option), Not(Patients have a BRAF V600E mutation))\\n--------\\n'}"
        ]
    }
}